A new study reveals why pancreatic cancer is so resistant to treatment and points to a promising way to overcome it. Researchers found that a specific group of immune cells, called tumor-associated macrophages, help tumors build an “immunosuppressive fortress” that protects them from chemotherapy and immunotherapy. The study identified a key pathway involving a lipid […]
Early trial results from the AURORAS-1 and JYP0015M101 studies show that ERAS-0015, a new pan-RAS “molecular glue,” may be highly effective in treating solid tumors with KRAS G12X mutations, including lung and pancreatic cancers. In patients with non-small cell lung cancer, the drug achieved response rates of 62% in those receiving second-line or later treatment,
ERAS-0015 Shows Strong Early Responses in RAS-Mutant Lung and Pancreatic Cancers Read More »
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to TERN-701, a new targeted drug for patients with Philadelphia chromosome–positive chronic myeloid leukemia who have already failed at least two prior treatments and do not carry the T315I mutation. Results from the Phase 1/2 CARDINAL trial, presented at the ASH Annual Meeting, showed
FDA Grants Breakthrough Status to TERN-701 for Hard-to-Treat CML Read More »
A study suggests that vitamin D may improve chemotherapy outcomes in women with breast cancer. Researchers gave 80 women over age 45 either 2,000 IU of vitamin D daily or a placebo during treatment. After six months, 43% of women taking vitamin D had no detectable cancer, compared to 24% in the placebo group. Most
Low-Dose Vitamin D Shows Promise in Boosting Breast Cancer Chemotherapy Outcomes Read More »
Researchers report that pancreatic cancer is not a disorganized mass, but a highly structured system of cooperating cells. In pancreatic ductal adenocarcinoma (PDAC), tumor growth depends on two distinct cell types working together. One group produces growth signals, while the other acts like stem cells that receive those signals and drive tumor expansion. The study
The U.S. Food and Drug Administration has accepted and granted Priority Review for zanidatamab (Ziihera) combined with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive advanced gastroesophageal cancer. A final decision is expected by August 25, 2026. The application is based on results from the HERIZON-GEA-01 trial, where the zanidatamab combination showed
The ACCESS trial shows that stem cell transplants no longer require a perfect donor match. Using post-transplant cyclophosphamide (PTCy), patients with mismatched unrelated donors achieved a 74.2% two-year survival rate without higher risks of chronic graft-versus-host disease or relapse. Even 7/8, 6/8, or 5/8 matches can now be effective. This approach has greatly expanded access
The COMPANION-002 trial tested Tovecimig (CTX-009) combined with paclitaxel in patients with advanced biliary tract cancer who had already received prior treatment. The combination worked better than paclitaxel alone, nearly doubling progression-free survival to 4.7 months compared with 2.6 months. Tumor response rates were also higher, with 17.1% of patients responding versus 5.3% in the
Long-term data and molecular monitoring are reshaping treatment for hormone receptor–positive breast cancer, with a stronger focus on personalized and proactive care. Results from the NATALEE trial show that adding ribociclib to endocrine therapy reduces recurrence in early-stage disease. At four years, invasive disease-free survival was 88.5% with ribociclib versus 83.6% without, and the benefit
In early 2016, the FDA approved several important new cancer and hematology treatments. cabozantinib (Cabometyx) was approved for advanced kidney cancer after prior therapy. In trials, it nearly doubled the time patients lived without disease progression compared to everolimus (7.4 vs. 3.8 months) and showed a median overall survival of 21.4 months. Common side effects